Home Biosciences Closes $15 Million Seed Financing Led by Redmile Group and Sofinnova Partners
Home Biosciences, Europe’s first venture builder fully dedicated to biotech, announced today a $15 million Seed financing led by Redmile Group and Sofinnova Partners.
Home Biosciences is the partner of choice for academics and scientists to transform their innovation into life changing therapies for patients. Every step of the way, Home Biosciences works together with leading scientific teams to build and grow sustainable businesses, by assembling the right expertise and structure. Each project is housed in a dedicated entity, a subsidiary, fully financed by Home Biosciences and led by teams entirely focused on the day-to-day execution of its projects with oversight from the Home Biosciences core management team.
"We are pleased to have such strong support from Redmile Group and Sofinnova Partners, two landmark investors in biotech, who recognize our potential to build a new type of biotech company, out of European science," said David Schilansky and Magali Richard, co-founders of Home-Biosciences. “Our ambition is to build a fully-fledged biotech company with an asset-centric operational model that aims to increase agility and R&D productivity. With the strong support of our shareholders, we look forward to leverage best-in-class science that will ultimately allow us to discover and deliver a new wave of first-in-class therapies.”
Proceeds from the financing will be used to accelerate the development of Home Biosciences’ pipeline while further strengthening its team. Specifically, the round will allow the company to advance its first venture, One Biosciences, as well as build a second one and a strong pipeline of projects. One Biosciences is focused on generating precision medicines by leveraging the power of single-cell technologies.
“Home Biosciences is pioneering an innovative model that fills an important gap in the European biotech ecosystem," said Antoine Papiernik, Managing Partner at Sofinnova Partners. “We are delighted to join forces with Redmile Group in supporting Europe’s first biotech venture builder in its mission to provide financial support and operational guidance, to create the groundbreaking therapies of the future.”
In connection with the Seed round, Ming Fang, a Managing Director of Redmile Group, and Antoine Papiernik, Managing Partner at Sofinnova Partners, will serve on the Board of Directors. They will join David Schilansky and Magali Richard, co-founders of Home Biosciences. An independent member of the Board is expected to be appointed in the near future.
About Home Biosciences
Home Biosciences is Europe’s first venture builder fully dedicated to biotech. Home Biosciences is the partner of choice for academics and scientists to transform their innovation into life changing therapies for patients. Every step of the way, Home Biosciences works with leading scientific teams to build and grow sustainable businesses, by assembling the right expertise and structure. With each of its projects housed in dedicated ventures and fully financed by Home Biosciences, its operating model allows full focus of its teams on scientific and operational excellence and rapid execution to significantly expedite and de-risk their discovery and development paths. For more information, visit: www.homebiosciences.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005152/en/
Contact information
Home Biosciences
David Schilansky & Magali Richard
contact@homebiosciences.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Colgate-Palmolive and WHO Foundation Announce Global Partnership on Oral Health20.1.2026 15:00:00 EET | Press release
Today, Colgate-Palmolive announced a new multi-year collaboration with the WHO Foundation to support the World Health Organization's work on oral health. The four-year funding commitment will help expand oral health education, support integration of oral health into national health systems, and raise awareness of oral health as a public health priority. This initiative builds on Colgate’s commitment to providing communities with oral health education and resources. The Company recently announced that the Colgate Bright Smiles, Bright Futures® program has reached approximately two billion children and their families around the world since 1991 with oral health education. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120050760/en/ “At Colgate-Palmolive, we are driven by our purpose to reimagine a healthier future for all – and to make more smiles. We’re launching this collaboration with the WHO Foundation given its unique
FGS Global Launches AI Advisory Practice and Acquires Threat Intelligence Firm Memetica20.1.2026 15:00:00 EET | Press release
FGS Global, the world's leading stakeholder strategy firm, today announced the launch of its AI Advisory practice and the acquisition of Memetica, a specialist technology consultancy in AI-driven threat detection and mitigation across social, dark web and fringe platforms. The new practice sits within FGS Global's recently formed AI and Innovation group led by Aaron Kwittken, Global Head of AI and Innovation. The AI Advisory practice builds on and consolidates FGS Global's deliberate, years-long investment in AI capabilities to support surging client demand for strategic and practical guidance on leveraging AI and emerging technologies to enhance communications efficacy, reputational defense and operational efficiencies. This critical work is supported by a global team of more than 200 strategists, analysts, engineers, developers, designers and data scientists across AI strategy, digital influence, campaigns, earned, paid and owned media, influencer engagement, special situations and c
CAS IP Finder Expands Intellectual Property Search Access Across Organizations20.1.2026 15:00:00 EET | Press release
CAS, a division of the American Chemical Society specializing in scientific knowledge management, announces complete functionality for CAS IP Finder™, powered by STN™. CAS STNext® customers can now access the full intellectual property search solution across all search methods, expanded content collections, and advanced analysis tools. Patent volume continues to grow, and scientific disciplines are increasingly interconnected, making intellectual property research more complex and increasing the risk of missed prior art. Organizations traditionally chose between empowering specialized searchers with comprehensive tools or providing limited capabilities to broader teams. CAS IP Finder eliminates that compromise by providing flexible access points that connect users of all experience levels to curated content and precise search tools. "As scientific and patent data grow in complexity, organizations need IP search solutions that enable access across entire teams," said Manuel Guzman, Pres
Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas20.1.2026 15:00:00 EET | Press release
Parse Biosciences and Graph Therapeutics (Graph) today announced a strategic partnership to create one of the largest and most comprehensive immune cell perturbation atlases. The collaboration will leverage Graph's lab-in-the-loop platform with Parse's GigaLab to profile hundreds of millions of cells from patients with immune diseases under systematic perturbation, making the immune system’s highly dynamic behavior accessible to AI-first drug discovery and development. This endeavor derisks and speeds up the development of new curative therapies for patients with immune-mediated diseases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120419953/en/ Autoimmune and immune-mediated diseases are driven by context- and patient-specific immune cell population responses, making it difficult for drug developers to identify drug targets and predict clinical outcomes. The partnership between Graph and Parse addresses this challenge
SEPHORA and OLIVE YOUNG Partner to Bring the Best of Korean Beauty to SEPHORA Consumers20.1.2026 15:00:00 EET | Press release
SEPHORA, the global leader in prestige beauty retail, and CJ OLIVE YOUNG, Korea's leading beauty and health retailer, announced today a new strategic partnership to bring the best curation of cutting-edge and sought-after Korean beauty to SEPHORA consumers around the world. The partnership will debut this fall as a visionary omnichannel partnership in the United States, Canada, Hong Kong SAR and Southeast Asia (Singapore, Malaysia, Thailand), with expansion into additional regions including the Middle East, the UK and Australia in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120395650/en/ The partnership will provide SEPHORA customers with a dedicated zone curated by OLIVE YOUNG online and in stores, allowing them to discover a unique assortment of the most popular Korean beauty brands, and the newest trend-driven Korean health and beauty products, all carefully curated by OLIVE YOUNG. The partnership also combine
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom